155 completed, 33 unknown, 9 recruiting, 8 not yet recruiting. 67 Not applicable, 55 Phase 2, 49 Phase 3, 18 Phase 1, 16 Phase 4.
Follow Dry Eye Disease: new trials by email Literature Review of Dry Eye Disease trials Research Report on Dry Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial BL1107 - Dry Eye Disease | Phase 2 | Not yet recruiting | Bausch & Lomb Incorporated | 20 | 2026-10-01 | 2026-08-21 |
| Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye CAM-101, Vehicle Control - Dry Eye Disease, Dry Eye | Phase 3 | Not yet recruiting | Cambium Bio Limited | 475 | 2026-10-01 | 2026-06-12 |
| Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease BUFY01 eye drops in single-dose containers, SVS20 eye drops in single-dose containers - Dry Eye Disease | Not applicable | Recruiting | TRB Chemedica International SA | 80 | 2026-09-01 | 2026-09-29 |
| Evaluation of Tears Naturale® Free and Tears Naturale® II Lubricant Eye Drops Tears Naturale Free lubricating eye drops, Tears Naturale II lubricating eye drops - Dry Eye Disease | Not applicable | Completed | Alcon Research | 132 | 2026-06-04 | 2026-10-07 |
| Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease Human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (sEV) eye drops. - Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles | Early Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2026-03-31 | 2026-06-03 |
| An Evaluation of the Safety and Tolerability of Ocular Lubricants FID123440 test formulation, FID123437 test formulation - Dry Eye Disease | Not applicable | Completed | Alcon Research | 124 | 2026-03-04 | 2026-08-11 |
| A Study to Evaluate the Safety and Effectiveness of Perfluorohexyloctane Eye Drops on Treatment of Dry Eye Disease (DED) Related to Meibomian Gland Dysfunction (MGD) Dry Eye Disease | Not yet recruiting | Xiamen Ophthalmology Center Affiliated to Xiamen University | 2000 | 2026-03-01 | 2026-03-09 | |
| A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease. Diagnostic tear fluid collection and ocular surface evaluation - Dry Eye Disease, Iron | Recruiting | Shanghai Changzheng Hospital | 52 | 2026-02-06 | 2026-02-10 | |
| Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® PRO-240, Optive® - Dry Eye Disease, Dry Eye Sensation | Phase 1 | Not yet recruiting | Laboratorios Sophia S.A de C.V. | 32 | 2026-01-30 | 2025-03-19 |
| Vit-A-Vision® Clinical Investigation Vit-A-Vision - Burning Eye, Irritation; Eyeball | Not applicable | Recruiting | OmniVision GmbH | 77 | 2025-12-19 | 2026-01-16 |
| A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease ABBV-444, REFRESH OPTIVE UD - Dry Eye Disease | Phase 3 | Completed | AbbVie | 261 | 2025-12-15 | 2026-09-17 |
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) - Dry Eye Disease | Phase 3 | Withdrawn | Bausch & Lomb Incorporated | 2025-12-01 | 2025-12-10 | |
| Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED). GRF312 5%, Placebo Comparator - Dry Eye Disease | Phase 2 | Completed | Instituto Grifols, S.A. | 103 | 2025-11-03 | 2026-06-16 |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane - Dry Eye Disease | Phase 2 | Completed | Bausch & Lomb Incorporated | 443 | 2025-10-24 | 2026-07-14 |
| Efficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease BUFY02 eye drops in single-dose containers, TRB02 eye drops in single-dose containers - Dry Eye Disease | Not applicable | Recruiting | TRB Chemedica International SA | 80 | 2025-09-25 | 2026-09-29 |
| Phase 2b Controlled Study IVW-1001 Ophthalmic Eyelid Wipe - Dry Eye Disease | Phase 2 | Completed | IVIEW Therapeutics Inc. | 30 | 2025-08-20 | 2026-03-27 |
| A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment Vevye®, Xiidra® - Dry Eye Disease | Phase 4 | Completed | Hoffmann-La Roche | 378 | 2025-07-09 | 2026-07-27 |
| A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients CsA-PG Ophthalmic Gel, CsA Ophthalmic Gel - Dry Eye Disease | Phase 3 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 396 | 2025-05-20 | 2025-04-29 |
| Efficacy of Lipid-containing Artificial Tears in the Treatment of Dry Eye Proluxx Artificial Tear Spray - Dry Eye Disease, Dry Eye | Not applicable | Not yet recruiting | University Hospital Sestre Milosrdnice | 50 | 2025-04-25 | 2025-05-02 |
| Evaluation of the Safety and Tolerability of Ocular Lubricants FID123359 test formulation, FID123360 test formulation, FID123361 test formulation - Dry Eye Disease | Not applicable | Terminated | Alcon Research | 73 | 2025-04-02 | 2025-08-17 |
Showing 20 of 217. Sign in to see all of them.
Dry Eye Syndromes (217) · Meibomian Gland Dysfunction (12) · Keratoconjunctivitis Sicca (10) · Cataract (4) · Conjunctivitis, Allergic (2) · Corneal Diseases (2) · Inflammation (2) · Sjogren's Syndrome (2) · Asthenopia (1) · Autoimmune Diseases (1) · Autonomic Nervous System Diseases (1) · Blepharospasm (1) · Constipation (1) · Disease Progression (1) · Ehlers-Danlos Syndrome (1)
Lacrimal Apparatus Diseases (217) · Eye Diseases (216) · Conjunctival Diseases (13) · Conjunctivitis (13) · Eyelid Diseases (13) · Keratitis (11) · Corneal Diseases (10) · Keratoconjunctivitis (10) · Immune System Diseases (6) · Lens Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Connective Tissue Diseases (3) · Mouth Diseases (3) · Salivary Gland Diseases (3)
Ophthalmic Solutions (13) · lifitegrast (10) · Nasal Sprays (9) · Cyclosporins (8) · Lubricant Eye Drops (6) · Varenicline (5) · diquafosol (4) · Loteprednol Etabonate (3) · Saline Solution (3) · perfluorohexyl-octan (3) · Cyclosporine (2) · Hyaluronic Acid (2) · betamethasone sodium phosphate (2) · cenegermin (2) · polyethylene glycol 400 (2)
Alcon Research (14) · Merck Sharp & Dohme LLC (8) · Bausch & Lomb Incorporated (7) · C.O.C. Farmaceutici S.r.l. (7) · Aerie Pharmaceuticals (5) · Novaliq GmbH (5) · Oyster Point Pharma, Inc. (5) · Aldeyra Therapeutics, Inc. (4) · Shire (4) · He Eye Hospital (3) · Nu Eyne Co., Ltd. (3) · Ophthalmic Consultants of Long Island (3) · Parion Sciences (3) · Sun Pharmaceutical Industries Limited (3) · Sylentis, S.A. (3)
United States (108) · Italy (16) · China (15) · Spain (7) · Australia (6) · Canada (5) · France (5) · South Korea (5) · Taiwan (5) · Germany (4) · Belgium (3) · Austria (2) · Egypt (2) · Iran (2) · Japan (2)
Pedram Hamrah, MD (3) · Tim McNamara, PharmD (3) · Amy Schaberg, BSN (2) · Donghui Lim, Ph. D., MD. (2) · Guanghao Qin (2) · Jose Boyer (2) · Kamran Hosseini, MD, PhD (2) · Martin Zinkernagel, Prof. Dr. Dr. (2)
PMID 42470519, PMID 15502479, PMID 36729473, PMID 37096956, PMID 41038456, PMID 10231609, PMID 10487426, PMID 12162486, PMID 15106919, PMID 17417148, PMID 18001233, PMID 19177348, PMID 21212181, PMID 22435675, PMID 22703523, PMID 23109740, PMID 23638722, PMID 24289915, PMID 24882753, PMID 25083776, PMID 25279127, PMID 25473263, PMID 25686388, PMID 26365210, PMID 26689380, PMID 26890669, PMID 27055211, PMID 27445067, PMID 27464993, PMID 28078849, PMID 28079022, PMID 28736336, PMID 28736340, PMID 28736342, PMID 28736344, PMID 28894606, PMID 28956287, PMID 29033270, PMID 30248890, PMID 30623968, PMID 30805209, PMID 31378996, PMID 32000988, PMID 32359968, PMID 32380019, PMID 33882269, PMID 34193498, PMID 34369983, PMID 34481407, PMID 34617974
2016 (1), 2019 (1), 2023 (1), R01EY022663 (1)